| References: |
Afuresertib inhibits the kinase activity of the E17K AKT1 mutant protein with EC50 of 0.2 nM. Afuresertib shows a concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3b, PRAS40, FOXO and Caspase 9. Overall 65% of the hematological cell lines are sensitive to afuresertib (EC50 < 1 μM). Among tested solid tumor cell lines, 21% have EC50 < 1 μM in response to afuresertib.Mice bearing BT474 breast tumor xenografts are dosed with afuresertib (p.o.) at 10, 30 or 100 mg/kg daily which results in 8, 37 and 61% TGI, respectively. Mice bearing SKOV3 ovarian tumor xenografts are treated with 10, 30 and 100 mg/kg afuresertib which results in 23, 37 and 97% TGI, respectively. For the detailed information of Afuresertib (GSK2110183), the solubility of Afuresertib (GSK2110183) in water, the solubility of Afuresertib (GSK2110183) in DMSO, the solubility of Afuresertib (GSK2110183) in PBS buffer, the animal experiment (test) of Afuresertib (GSK2110183), the cell expriment (test) of Afuresertib (GSK2110183), the in vivo, in vitro and clinical trial test of Afuresertib (GSK2110183), the EC50, IC50,and affinity,of Afuresertib (GSK2110183), For the detailed information of Afuresertib (GSK2110183), the solubility of Afuresertib (GSK2110183) in water, the solubility of Afuresertib (GSK2110183) in DMSO, the solubility of Afuresertib (GSK2110183) in PBS buffer, the animal experiment (test) of Afuresertib (GSK2110183), the cell expriment (test) of Afuresertib (GSK2110183), the in vivo, in vitro and clinical trial test of Afuresertib (GSK2110183), the EC50, IC50,and affinity,of Afuresertib (GSK2110183), Please contact DC Chemicals. |
